No Picture
Trading Ideas

UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said in a statement Friday that the approval meant it had all the needed regulatory approvals and would close the acquisition on Wednesday. Amgen has agreed to buy Celgene’s Otezla business, the company said in a statement. …read more […]

No Picture
Trading Ideas

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said in a statement Friday that the approval meant it had all the needed regulatory approvals and would close the acquisition on Wednesday. Amgen has agreed to buy Celgene’s Otezla business, the company said in a statement. …read more […]

No Picture
Trading Ideas

T-Mobile’s Legere Isn’t Taking WeWork Job, Relieving Investors

(Bloomberg) — T-Mobile US Inc. Chief Executive Officer John Legere isn’t taking a job running WeWork, contrary to speculation this week, a person familiar with the matter said.Legere, 61, is sticking with T-Mobile for now, according to the person, who asked not to be identified because the deliberations are private. CNBC reported earlier that Legere wasn’t going to WeWork, sending the shares up as much as 3.5% on Friday.Legere, a shaggy-haired, self-appointed industry rebel, has led a comeback at T-Mobile, culminating in a deal last year to merge with Sprint Corp. That transaction hasn’t yet cleared regulatory hurdles, and the …read more […]